Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
about
The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder CancerManagement of carcinoma in situ of the bladder: best practice and recent developmentsS6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancerAn orthotopic bladder cancer model for gene delivery studies.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy.Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study.Modelling bladder cancer in mice: opportunities and challenges.Mouse models of human bladder cancer as a tool for drug discovery.Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cellsThe mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progressionAMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms.Establishment of an orthotopic mouse non-muscle invasive bladder cancer model expressing the mammalian target of rapamycin signaling pathway.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.PTEN loss in the continuum of common cancers, rare syndromes and mouse models.Exploring molecular genetics of bladder cancer: lessons learned from mouse modelsmTOR inhibitors in urinary bladder cancer.The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivoThe role of WNT signalling in urothelial cell carcinoma.Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients.Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway.Urinary Tract Infection in a Small Animal Model: Transurethral Catheterization of Male and Female Mice.miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells.Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Current clinical trials in non-muscle invasive bladder cancer.A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
P2860
Q26738516-7C9EB24C-5DC1-45F4-9936-04FBF331A54CQ26775772-C9691BE1-AD1A-4887-8105-F22AED3851FDQ28477972-9900B875-1397-4603-A665-49B5ED0C0366Q33570888-7B61AA39-C0B7-4771-8C97-E217AAE5AC8CQ33640357-FADC1B2E-89D0-4175-A59C-319A5F348BBFQ33886553-EC578218-8BA7-4028-A64F-58A1C584EFCCQ33933049-25543B25-1807-4270-9FA3-01143075AFDCQ35050634-671EB5B2-B3D7-491E-87C7-044EBF8AD63EQ35106935-FDEDBBAE-79AC-4771-8BB5-F29DCB4EDDB7Q35131862-A131169F-DC4B-4677-A114-8DEB2D842E98Q35151995-E1DA1FF0-50EE-4190-A663-6FC19CCBF4B4Q35285703-FCBF5429-CDD9-4A3B-A016-B177974B0E5CQ35738385-0243164E-3F88-4C4A-B795-AD499A670C88Q35813290-2DF070A1-2D80-44E2-9F88-1FB8CA2D0447Q36027204-52E2A5E1-189F-4BDC-AB91-307A127804A1Q36384361-AFE24C4B-0BC7-4905-BAAE-D83CC8225566Q36541067-56584752-5FB0-42F1-9292-BEF563019700Q36665063-EC2D7AB5-283F-40B8-B241-CEC323F37E0AQ37016565-F77AB119-D9DA-4020-98C9-02E5F7055095Q37482647-95E7D892-248C-4315-B775-A0F1040358A1Q37622192-9D9A7D5D-4221-4D51-9C22-3FB53C5E249AQ37775890-D06843DC-4A2C-4538-9B74-B335A654368EQ37856722-C3E1D9A2-DB07-4AD6-911E-F1FC49BFB87BQ37994164-47206634-9B4B-46A9-A56D-0133D5B07FC3Q38737064-FC909704-0443-45DB-8C81-460FF34A598FQ39042097-67097078-29F4-44CC-B892-F164D7C83B2FQ40642338-F84CC0D0-CEC8-4886-99AC-C81907831117Q41339763-1FA2EEB1-3148-4895-93BB-3D6FBA0BCEBFQ41913207-D1A17218-3F21-4E29-A903-1DB5ACB642DCQ47141760-BCCDB969-C8E9-44A3-82D7-A047A353F7E4Q47559300-D325B05C-BDE6-4531-9060-9A78AC99C639Q49425667-A56E5447-961C-4F97-B28F-6DA4185B39CAQ52602391-93D34858-32D1-4386-AED2-3DA62D829A75Q53124991-30202FB2-D751-4C9E-A806-372AF2D9439CQ54285690-A744A639-EC14-4EA7-B16C-D8F296359E35
P2860
Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intravesical delivery of rapam ...... of progressive bladder cancer.
@en
Intravesical delivery of rapam ...... of progressive bladder cancer.
@nl
type
label
Intravesical delivery of rapam ...... of progressive bladder cancer.
@en
Intravesical delivery of rapam ...... of progressive bladder cancer.
@nl
prefLabel
Intravesical delivery of rapam ...... of progressive bladder cancer.
@en
Intravesical delivery of rapam ...... of progressive bladder cancer.
@nl
P2093
P2860
P1476
Intravesical delivery of rapam ...... of progressive bladder cancer.
@en
P2093
Anna M Puzio-Kuter
Catherine M Seager
Cory Abate-Shen
James Mc Kiernan
Shalini Jain
Trushar Patel
P2860
P304
P356
10.1158/1940-6207.CAPR-09-0169
P577
2009-12-01T00:00:00Z